Given the reported similarities between the pathogenesis of RA and that of atherosclerosis the evidence of protective effects with hydroxychloroquine and/or TNF from such trials might translate into the possible repurposing of these drugs for cardiovascular risk management in other, non-autoimmune, patient populations. This evidence concerns the gene TNF and atherosclerosis.